- Home
- MTCH vs CORT Comparison
MTCH vs CORT Comparison
Compare MTCH & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTCH | CORT |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.6B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | MTCH | CORT |
|---|---|---|
| Price | $32.61 | $81.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $35.27 | ★ $130.20 |
| AVG Volume (30 Days) | ★ 3.1M | 852.0K |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.15 | 0.87 |
| Revenue | ★ $3,469,367,000.00 | $741,172,000.00 |
| Revenue This Year | $2.06 | $23.79 |
| Revenue Next Year | $3.46 | $40.97 |
| P/E Ratio | ★ $15.14 | $94.20 |
| Revenue Growth | N/A | ★ 17.92 |
| 52 Week Low | $26.39 | $49.00 |
| 52 Week High | $39.20 | $117.33 |
Technical Indicators
Market Signals| Indicator | MTCH | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 51.07 |
| Support Level | $32.19 | $78.07 |
| Resistance Level | $34.35 | $89.00 |
| Average True Range (ATR) | 0.74 | 3.47 |
| MACD | -0.14 | -0.31 |
| Stochastic Oscillator | 18.75 | 37.54 |
Price Performance
Historical ComparisonAbout MTCH Match Group Inc.
Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. The company generates the majority of its revenue from the Tinder segment.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.